Skip to main content
custom logo
Investing in EU Biotech IP – What Works?
A Vital Transformation led consortium including Pfizer, the U.S. Chamber of Commerce and Medtrack by Informa investigated the relationship between public funding and private investment into new innovative therapies and the supporting system of Intellectual Property (IP). The results were released at the 2018 edition of the European Health Forum Gastein.

The project developed original research that identified the success factors that create high-value EU biotech companies and the role of IP in creating an ecosystem where investors are willing to lose everything 92% of the time, in order to fund the 8% of medical breakthroughs that occasionally succeed.

Dec 4, 2018 2:00 PM in Brussels

custom image
Webinar is over, you can not register now. If you have any questions, please contact Webinar host: Petra Naster.